HomeAI · summaries
Storia in 4 fonti
Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability
Gilead Sciences’ HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time. | Gilead’s HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time, as highlighted by CEO Daniel O’Day. But one group of analysts is raising doubts about the long-term growth of Yeztugo, the company’s much-touted long-acting PrEP option.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
investors.com
Gilead Slumps As Long-Term Uncertainty Clouds Big HIV Beat
Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend.
- ·
biopharmadive.com
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
